Depression Treatment: Parental Perceived Benefits of OROS-Methylphenidate Treatment for the Child With Attention-Deficit/Hyperactivity Disorder and for Parents Themselves.

Parental Perceived Benefits of OROS-Methylphenidate Treatment for the Child with Attention-Deficit/Hyperactivity Disorder and for Parents Themselves.

Filed under: Depression Treatment

Pharmacopsychiatry. 2013 Jan 30;
Kim JW, Park S, Kim BN, Shin MS, Cho SC, Kim JH, Son JW, Shin YM, Chung US, Han DH

Given the shortage of studies on parental perceived benefits of OROS-methylphenidate treatment in Asian populations, we assessed parental response to OROS-methylphenidate treatment of Korean children with attention-deficit/hyperactivity disorder (ADHD), in relation to children’s academic performance and behavioral symptoms as well as parental rearing stress and depressive symptoms.We enrolled 132 medication-naïve children with ADHD into a multicenter, open-label, 12-week trial of OROS-MPH. The outcome measures were the ADHD rating scale-IV (ADHD-RS), the comprehensive attention test and academic performance rating scale, and the clinical global impression (CGI)-severity/improvement instrument (for the children) and Beck depression inventory and parenting stress index (for their parents).We found parent-perceived improvements in children’s ADHD-related behavioral symptoms and academic function and their parents’ depressive symptoms and parenting stress. Investigator-rated ADHD symptoms and subjects’ neuropsychological function were also improved (p<0.001).Parents of Korean children with ADHD perceive that OROS-methylphenidate treatment improves their children's academic function and behavior as well as their own child-rearing stress and emotional state. These findings must be interpreted with caution, due to a non-comparative open-label trial. HubMed – depression

Cocoa polyphenols enhance positive mood states but not cognitive performance: A randomized, placebo-controlled trial.

Filed under: Depression Treatment

J Psychopharmacol. 2013 Jan 29;
Pase MP, Scholey AB, Pipingas A, Kras M, Nolidin K, Gibbs A, Wesnes K, Stough C

This study aimed to examine the acute and sub-chronic effects of cocoa polyphenols on cognition and mood. In a randomized, double-blind study, healthy middle-aged participants received a dark chocolate drink mix standardized to contain 500 mg, 250 mg or 0 mg of polyphenols (placebo) in a parallel-groups design. Participants consumed their assigned treatment once daily for 30 days. Cognition was measured with the Cognitive Drug Research system and self-rated mood with the Bond-Lader Visual Analogue Scale. Participants were tested at baseline, at 1, 2.5 and 4 h after a single acute dose and again after receiving 30 days of treatment. In total, 72 participants completed the trial. After 30 days, the high dose of treatment significantly increased self-rated calmness and contentedness relative to placebo. Mood was unchanged by treatment acutely while cognition was unaffected by treatment at all time points. This randomized controlled trial is perhaps the first to demonstrate the positive effects of cocoa polyphenols on mood in healthy participants. This provides a rationale for exploring whether cocoa polyphenols can ameliorate the symptoms associated with clinical anxiety or depression.
HubMed – depression

The Oklahoma thrombotic thrombocytopenic purpura-haemolytic uraemic syndrome Registry. A model for clinical research, education and patient care.

Filed under: Depression Treatment

Hamostaseologie. 2013 Jan 31; 33(2):
George JN, Vesely SK, Terrell DR, Deford CC, Reese JA, Al-Nouri ZL, Stewart LM, Lu KH, Muthurajah DS

The Oklahoma Thrombotic Thrombocytopenic Purpura-Haemolytic Uraemic Syndrome (TTP-HUS) Registry has a 24 year record of success for collaborative clinical research, education, and patient care. This article tells the story of how the Registry began and it describes the Registry’s structure and function. The Registry provides a model for using a cohort of consecutive patients to investigate a rare disorder. Collaboration between Oklahoma, United States and Bern, Switzerland has been the basis for successful interpretation of Registry data.Registry data have provided new insights into the evaluation and management of TTP. Because recovery from acute episodes of TTP has been assumed to be complete, the increased prevalence of hypertension, diabetes, depression, and death documented by long-term follow-up was unexpected. Registry data have provided opportunities for projects for students and trainees, education of physicians and nurses, and also for patients themselves. During our follow-up, patients have also educated Registry investigators about problems that persist after recovery from an acute episode of TTP. Most important, Registry data have resulted in important improvements for patient care.
HubMed – depression

Find More Depression Treatment Information…